Nanjing Pharmaceutical Group Company Limited (SHA:600713)
5.12
-0.07 (-1.35%)
Nov 18, 2026, 3:00 PM CST
SHA:600713 Revenue
Nanjing Pharmaceutical Group Company had revenue of 13.86B CNY in the quarter ending September 30, 2026, with 5.29% growth. This brings the company's total for the last twelve months to 55.52B, up 3.01% year-over-year. In the year 2025, Nanjing Pharmaceutical Group Company had annual revenue of 54.96B with 2.36% growth. That makes Nanjing Pharmaceutical Group Company the 1,728th largest company in the world by revenue and 182nd in China.
Revenue (ttm)
55.52B
Revenue Growth
+3.01%
P/S Ratio
0.12
Revenue / Employee
11.82M
Employees
4,697
Market Cap
6.70B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.96B | 1.27B | 2.36% |
| Dec 31, 2024 | 53.70B | 106.51M | 0.20% |
| Dec 31, 2023 | 53.59B | 3.37B | 6.71% |
| Dec 31, 2022 | 50.22B | 5.10B | 11.30% |
| Dec 31, 2021 | 45.12B | 5.31B | 13.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Int'l Group | 34.69B |
| Yifan Pharmaceutical | 4.93B |
| Zhejiang Jolly Pharmaceutical Co.,LTD | 3.27B |
| GuangYuYuan Chinese Herbal Medicine | 1.31B |
| Zhejiang Wolwo Bio-Pharmaceutical | 1.12B |
| Hangzhou Minsheng Healthcare | 902.62M |
| Chongqing Lummy Pharmaceutical | 720.01M |
| Hangzhou Bio-Sincerity Pharma-Tech | 617.95M |